Close Menu

NEW YORK (GenomeWeb) – Inivata said today that Medicare administrative contractor Palmetto GBA has finalized its draft local coverage determination (LCD) for the company's liquid biopsy lung cancer test, InVisionFirst-Lung.

The policy, which becomes effective April 8, provides specific coverage for the test for all fee-for-service Medicare patients in the US with advanced (Stage IIIB/IV) NSCLC who meet specific clinical criteria.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports that gene therapy approaches are tackling sickle cell disease, but that the cost of treatment is a concern.

The Washington Post reports that a US Senate committee voted this week to approve the nomination of Stephen Hahn to lead the Food and Drug Administration.

One gene regulates hundreds of others to influence facial development, according to New Scientist.

In Nature this week: resources for single-cell analysis, little overlap in the microRNAs used by Salmonella and Shigella to infect host cells, and more.